Emerging Leader Lectureships

The purpose of the Emerging Leader Lectureships is to recognise young scientists and clinical scientists within the region and encourage them as the ‘rising stars’ of the future.

Nominees

  • Nominees must be forty-five (45) years of age or younger at the time the nomination is submitted.
  • Provide their CV and title of their lecture and abstract.
  • Demonstrate excellence in research, and that they are an outstanding contributor in their age group.
  • In principal be established in their own right i.e. Associate Professor.
  • Must submit a review article for publication in the journal.
  • Provide their submission via their local society.
  • Be received by 31 July each year.

Conditions

  • Maximum of one (1) nominee per country.
  • A total of two (2) lectureships per meeting are awarded.
  • The Trustees of the JGH Foundation will make the final decision on the selection of the two (2) lecturers.

Funding

  • Return economy class airfare between home city and the venue for APDW.
  • Accommodation in a single room at one of the conference hotels to cover the night before speaking engagement commences until and including the night after participation (maximum 4 nights).
  • Honorarium of US$1,000 for submission of manuscript for publication in JGH at the time of the meeting.

Manuscript

Each lecturer is required to submit a manuscript for publication in the Journal of Gastroenterology and Hepatology (JGH) that covers the content of their lecture. The manuscript should be structured as a review article between 2,500-3,000 words. For information on JGH style guidelines please see the Wiley-Blackwell House Style Guide

Past Award Recipients

Year Recipient City Topic
2017 Grace Wong Hong Kong Non-invasive assessments for liver fibrosis - the crystal ball we long for
Norihisa Ishimura Shimane Eosinophilic esophagitis and proton pump inhibitor-responsive eosinophilia: distinct disease entities?
2016 Philip Chiu Hong Kong Innovation and Advances in Endoscopic Surgery
Ming-Lung Yu Kaohsiung Treatment of chronic HCV infection: From Response-guided therapy to Resource-guided therapy in the transition era from Interferon-containing to Interferon-free regimens
2015 Chun-Ying Wu Taichung A Roadmap to Prevent Digestive Cancers: From molecular studies, clinical researches, big data analyses, to personal risk prediction and biochips development
Young-Suk Lim Seoul Achieving the Goal of Hepatitis B Treatment
2014 Siew Chien Ng Hong Kong Inflammatory bowel disease in Asia: emergence of a "Western Disease"
Yock Young Dan Singapore Liver's Holy Grail? - The Somatic Liver Stem Cell and its Therapeutic Applications
2013 Katsunori Iijima Sendai Involvement of luminal nitric oxide in the pathogenesis of gastro-esophageal reflux disease spectrum
Chun-Jen Liu Taipei Dual HCV and HBV Infection: Resolved and unresolved issues
2012 Vincent Wai Sung, Wong Hong Kong Nonalcoholic Fatty Liver Disease in Asia - A Story of Growth
Jae Hee Cheon Seoul Genetics and epigenetics in the pathogenesis of inflammatory bowel diseases
2011 Manoj Sharma New Delhi Chronic hepatitis B infection and normal ALT: treat or not to treat?
Ping-I Hsu Kaohsiung A new look at antiplatelet agent-related peptic ulcer: An update of prevention and treatment
2010 Henry Lik-Yuen Chan Hong Kong The decoding of HBV genomics by a clinician
Khek-Yu Ho Singapore From GERD to Barrett's oesophagus: Is the pattern in Asia mirroring that in the West?
2009 Bor-Shyang Sheu Taipei Helicobacter Pylori Colonization of the Human Gastric Epithelium: the First Step of Bug & Novel Target for Us.
Rong-Nan Chien Taipei On Treatment Monitoring of Chronic Hepatitis B Virus Infection: an Asian Pacific Perspective
2008 Ming-Shiang Wu Taipei Proteomic identifications of biomarkers related to Helicobacter pylori-associated gastroduodenal diseases: challenges and opportunity
Che-Yuen Justin Wu Hong Kong Gastroesophageal reflux disease:An Asian perspective
2007 Kai-Chun Wu Xian Molecular basis of therapeutic approaches to gastric cancer
Isao Sakaida Japan Autologous bone marrow cell infusion ( ABMI ) therapy for liver cirrhosis